Top

Published in:

01-04-2017 | Clinical Study

LAPTM4B-35 is a novel prognostic factor for glioblastoma

Authors: Xiaoshud Dong, Kaoru Tamura, Daisuke Kobayashi, Noboru Ando, Kazutaka Sumita, Taketoshi Maehara

Published in: Journal of Neuro-Oncology | Issue 2/2017

Abstract

Lysosome-associated protein transmembrane-4 beta (LAPTM4B)-35, a newly identified cancer-associated gene, is overexpressed in a wide variety of malignant tumors. However, studies of its expression and role in glioma have not yet been reported. This study aimed to investigate the expression and the role of LAPTM4B-35 in glioma and to assess its value as a prognostic factor. Seventy-seven glioma cases (Grade II in 18 patients, Grade III in 16 and Grade IV in 43) were immunohistochemically examined for LAPTM4B-35, pAkt, factor VIII and Ki-67 expressions. The LAPTM4B-35 expression score of Grade II gliomas was lower than those of Grade III–IV gliomas (p < 0.05), while the difference between Grade III and IV gliomas was not statistically significant. Of the 43 patients with glioblastoma (GBM), 27 (62.8%) had high LAPTM4B-35 expression, which was associated with high tumor micro-vessel density and pAkt activation. The median progression-free survival (PFS) of GBM patients with high LAPTM4B-35 expression was 5.13 months, significantly shorter than that of those with low LAPTM4B-35 expression (12.0 months, p < 0.0001). The median overall survival (OS) of GBM patients with high LAPTM4B-35 expression was 12.5 months, again significantly shorter than that of those with low LAPTM4B-35 expression (29.6 months, p < 0.0001). Multivariate analysis indicated LAPTM4B-35 to be an independent prognostic factor for PFS and OS of GBM patients. Our findings show LAPTM4B-35 to be strongly associated with tumor proliferation, tumor angiogenesis and poor outcomes of GBM patients, suggesting LAPTM4B-35 to potentially be applicable as a novel prognostic marker and even to possibly play a role in improving GBM treatment.

Available only for authorised users

Ohgaki H (2009) Epidemiology of brain tumors. Methods Mol Biol 472:323–342CrossRef

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17:iv1–iv62CrossRef

Jhanwar-Uniyal M, Labagnara M, Friedman M, Kwasnicki A, Murali R (2015) Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers (Basel) 7:538–555CrossRef

Tamber MS, Rutka JT (2003) Pediatric supratentorial high-grade gliomas. Neurosurg Focus 14:e1CrossRef

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRef

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRef

Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X, Ye DX (2003) Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22:5060–5069CrossRef

Yang H, Xiong F, Qi R, Liu Z, Lin M, Rui J, Su J, Zhou R (2010) LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 101:363–369CrossRef

Tang H, Tian H, Yue W, Li L, Li S, Gao C, Si L, Qi L, Lu M (2014) Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer. Med Oncol 31:974. doi:10.1007/s12032-014-0974-8 CrossRefPubMed

10.

Kasper G, Vogel A, Klaman I, Grone J, Petersen I, Weber B, Castanos-Velez E, Staub E, Mennerich D (2005) The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 224:93–103CrossRef

11.

Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L, Zhou R (2008) LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 20:1077–1083PubMed

12.

Zhou L, He XD, Chen J, Cui QC, Qu Q, Rui JA, Zhao YP (2007) Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer 43:809–815CrossRef

13.

Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi C, Wang A, Sheng B, Li L, Xu Y (2014) Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. PloS one 9:e91069CrossRef

14.

Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y, Huang Y (2012) Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg 204:677–683CrossRef

15.

Xiao M, Jia S, Wang H, Wang J, Huang Y, Li Z (2013) Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. J Cancer Res Clin Oncol 139:661–667CrossRef

16.

Yang H, Xiong F, Wei X, Yang Y, McNutt MA, Zhou R (2010) Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett 294:236–244CrossRef

17.

Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16:214–218CrossRef

18.

Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao GZ, Zhou RL (2010) LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29:5785–5795CrossRef

19.

Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M, Ohno K (2010) Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg 113:310–318CrossRef

20.

Carvalho S, Milanezi F, Costa JL, Amendoeira I, Schmitt F (2010) PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch 456:235–243CrossRef

21.

Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Backlund LM, CollinsVP, Ichimura K (2012) MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. Int J Cancer 131:1104–1113CrossRef

22.

Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297–310CrossRef

23.

Burris HA 3rd (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71:829–842CrossRef

24.

Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo J, Wang Y, Xu Y (2015) miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget 6:6092–6104PubMedPubMedCentral

25.

Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW (2015) Mechanisms regulating glioma invasion. Cancer Lett 362:1–7CrossRef

26.

Tan X, Sun Y, Thapa N, Liao Y, Hedman AC, Anderson RA (2015) LAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. EMBO J 34:475–490CrossRef

Title: LAPTM4B-35 is a novel prognostic factor for glioblastoma
Authors: Xiaoshud Dong
Kaoru Tamura
Daisuke Kobayashi
Noboru Ando
Kazutaka Sumita
Taketoshi Maehara
Publication date: 01-04-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2369-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

LAPTM4B-35 is a novel prognostic factor for glioblastoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide

Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease

Erratum to: LAPTM4B-35 is a novel prognostic factor for glioblastoma

Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status

Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells

Early postoperative tumor progression predicts clinical outcome in glioblastoma—implication for clinical trials